About 20% of Asian and Caucasian populations carry this mutation and fail to produce GlcNAc conjugates, hence, if these bile acids were to be used as a biomarker, many cases would be missed for NPC and also NPB, LAL deficiency and SLOS. This evidence concerns the gene LIPA and nasopharyngeal carcinoma.